Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates

被引:73
作者
Verthelyi, D
Klinman, DM
机构
[1] US FDA, Ctr Biol Evaluat & Res, Sect Retroviral Immunol, Bethesda, MD 20892 USA
[2] US FDA, Div Therapeut Prot, Bethesda, MD 20892 USA
关键词
innate immunity; CpG ODN; primates; human; vaccines; immunoprotection; allergies; cancer; safety;
D O I
10.1016/S1521-6616(03)00202-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Oligodeoxynucleotides (ODN) containing CpG motifs mimic the ability of microbial DNA to activate the innate immune system. The resultant response limits the early spread of infectious organisms while promoting the development of adaptive immunity. CpG ODN show promise as vaccine adjuvants and in the treatment of asthma, allergy, infection, and cancer. Due to evolutionary divergence in CpG recognition between species, CpG ODN that are most active in rodents are poorly immunostimulatory in primates. Thus, evidence that CpG ODN have therapeutic activity in mice must be confirmed in primates. Two distinct types of CpG ODN were identified that stimulate primate PBMC. D-type ODN trigger plasmacytoid DC to secrete IFNalpha, monocytes to mature into functionally active DC, and NK cells to secrete IFNgamma. K-type ODN stimulate B cells and monocytes to proliferate and secrete IgM, IL-10, and/or IL-6. In vivo studies in nonhuman primates indicate that proinflammatory or humoral immune responses can be selectively facilitated by judicious use of these distinct types of ODN.
引用
收藏
页码:64 / 71
页数:8
相关论文
共 77 条
[41]  
Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO
[42]  
2-U
[43]   CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells [J].
Krug, A ;
Rothenfusser, S ;
Selinger, S ;
Bock, C ;
Kerkmann, M ;
Battiany, J ;
Sarris, A ;
Giese, T ;
Speiser, D ;
Endres, S ;
Hartmann, G .
JOURNAL OF IMMUNOLOGY, 2003, 170 (07) :3468-3477
[44]   Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9):: frequencies, pairwise linkage disequilibrium, and haplotypes in three US ethnic groups and exploratory case-control disease association studies [J].
Lazarus, R ;
Klimecki, WT ;
Raby, BA ;
Vercelli, D ;
Palmer, LJ ;
Kwiatkowski, DJ ;
Silverman, EK ;
Martinez, F ;
Weiss, ST .
GENOMICS, 2003, 81 (01) :85-91
[45]   Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides [J].
Leifer, CA ;
Verthelyi, D ;
Klinman, DM .
JOURNAL OF IMMUNOTHERAPY, 2003, 26 (04) :313-319
[46]   CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants [J].
Lipford, GB ;
Bauer, M ;
Blank, C ;
Reiter, R ;
Wagner, H ;
Heeg, K .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (09) :2340-2344
[47]   Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants [J].
McCluskie, MJ ;
Davis, HL .
VACCINE, 2000, 19 (4-5) :413-422
[48]  
MESSINA JP, 1991, J IMMUNOL, V147, P1759
[49]   VACCINATION OF HUMANS AGAINST CUTANEOUS LEISHMANIASIS - CELLULAR AND HUMORAL IMMUNE-RESPONSES [J].
NASCIMENTO, E ;
MAYRINK, W ;
DACOSTA, CA ;
MICHALICK, MSM ;
MELO, MN ;
BARROS, GC ;
DIAS, M ;
ANTUNES, CMF ;
LIMA, MS ;
TABOADA, DC ;
LIU, TY .
INFECTION AND IMMUNITY, 1990, 58 (07) :2198-2203
[50]  
Obermeier F, 2002, EUR J IMMUNOL, V32, P2084, DOI 10.1002/1521-4141(200207)32:7<2084::AID-IMMU2084>3.0.CO